Please login to the form below

BACE inhibitor

This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

The additional study could also include an arm combining BAN2401 with Eisai’s BACE inhibitor elenbecestat, a drug class that has also seen a string of failures in late-stage testing ... BACE inhibitors are designed to an enzyme involved in the

Latest news

Eisai to tackle dementia in new US research facility

Merck &Co has also seen failure with its BACE1 inhibitor verubecestat, which also led to the drug’s abandonment. ... However Eisai, which also has a BACE inhibitor elenbecestat in late-stage testing, has several dementia candidates in its pipeline, and
Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
Merck BACE inhibitor adds to litany of Alzheimer's trial failures

The latest disappointment comes from a phase II/III study of Merck &Co's BACE inhibitor verubecestat, a drug designed to block the formation of the amyloid plaques that are a ... verubecestat. Merck (known as MSD outside the US and Canada) is currently
Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running ... secretase inhibitor semagacestat.

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Latest Intelligence

Deal Watch table for September 2014

525. AstraZeneca / Lilly. Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
Pharma deals during September 2014

Rhizen to change their deal from a 50/50 joint venture to a global (excluding India) licence. The product, an oral PK13 delta inhibitor appears to have completed phase 2 the ... AstraZeneca and Lilly have announced a joint development and
Eisai: Bucking the trend with R&D growth

BACE inhibitor E2609.